Veracyte Has Released Our Inaugural ESG Report Read More
Search Open Mobile Menu
Veracyte Has Released Our Inaugural ESG Report Read More

Veracyte® Investor Relations

Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product
Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product SOUTH SAN FRANCISCO, Calif.--- BUSINESS WIRE ---Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company’s first product
View HTML
Toggle Summary New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples South San Francisco, Calif.--- PRNewswire ---Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial
View HTML

Events

Date Event Details
Summary Toggle Jun 6, 2023 9:40 AM EDT
William Blair 43rd Annual Growth Stock Conference
Summary Toggle Jun 13, 2023 6:20 PM EDT
Goldman Sachs 44th Annual Global Healthcare Conference

Presentations

Title Documents

Corporate Presentation May 2023